polycythemia vera
DESCRIPTION
Polycythemia Vera. Andrea Brassard NURS 7724 November 25, 2002. Objectives. Upon completion of this program the participant will: 1. Define polycythemia vera (PV). 2. Describe the epidemiology of PV. 3. Identify the symptoms and signs of PV 4. Describe how PV is diagnosed. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/1.jpg)
Polycythemia Vera
Andrea Brassard
NURS 7724
November 25, 2002
![Page 2: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/2.jpg)
Objectives
Upon completion of this program the participant will:
1. Define polycythemia vera (PV).
2. Describe the epidemiology of PV.
3. Identify the symptoms and signs of PV
4. Describe how PV is diagnosed.
5. Identify therapeutic modalities for PV.
6. Identify the complications of PV.
![Page 3: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/3.jpg)
PV: Definition
• A chronic, progressive blood disorder
• Caused by an abnormality in certain immature cells in the bone marrow
• Stimulates an overproduction of RBCs, WBCs, & platelets
http://hopkinsafter50.com/html/newsletter/ha0502
![Page 4: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/4.jpg)
PV: Definition
• A neoplastic (clonal) stem cell disorder
• probably arising in a pluripotent hematopoietic progenator cell
• which leads to excessive production of all myeloid cell lines
• predominantly red blood cells(Wasserman, Berk, & Berlin, 1995)
![Page 5: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/5.jpg)
![Page 6: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/6.jpg)
Epidemiology of PV
• Relatively rare disorder
• Annual incidence 0.6 to 1.6 per million per year
• Ages 50 to 70 peak years
• Slightly more prevalent in males
• More common in Jews, less common in blacks
• Possible genetic predisposition
mpd_man.gif
![Page 7: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/7.jpg)
PV: Symptoms
• The symptoms and signs of PV can be attributed to the expanded total blood volume and the increased blood viscosity.
• The onset of PV is insidious and symptoms frequently precede a diagnosis of PV by several years.
• Patients may be asymptomatic or have vague or non-specific complaints
![Page 8: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/8.jpg)
Symptoms of PV
A large study of PV revealed the following symptoms and reported frequency
headache (48%) weakness (47%) pruritus(43%) dizziness (43%) sweating (33%)
visual disturbances (31%)
weight loss (29%) paresthesias (29%)
dyspnea (26%) joint symptoms (26%)
epigastric distress (24%)
(Wasserman, Berk, & Berlin, 1995)
![Page 9: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/9.jpg)
Signs of PV on Physical Exam
• Enlarged spleen (70%)
• Skin plethora (ruddy cyanosis) (67%)
• Conjunctival plethora (59%)
• Fundoscopic - engorged vessels (46%)
• Enlarged liver (40%)
• Systolic B/P > 140 (72%)
• Diastolic B/P > 90 (32%)(Wasserman, Berk, & Berlin, 1995)
![Page 10: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/10.jpg)
![Page 11: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/11.jpg)
![Page 12: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/12.jpg)
![Page 13: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/13.jpg)
![Page 14: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/14.jpg)
Diagnosis of PV
• Elevated hematocrit is first clue• REFER TO HEMATOLOGIST! • Additional Diagnostic tests include:
CBC and peripheral smear
Bone marrow aspiration and biopsy
Leukocyted alkaline phosphatase
Abdominal ultrasound and/or CT; IVP
Erythropoetin level; Serum B12; ABG
![Page 15: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/15.jpg)
![Page 16: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/16.jpg)
Laboratory features in PV
• Elevated red cell mass
• Red cell morphology
• Leukocytosis
• Mild basophilia
• Mild to moderate thrombocytosis
![Page 17: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/17.jpg)
PV: Typical CBC
WBC 18 [4-11] Neuts 14 [2-7.5]
hgb 20 [14-18] Lymphs 2 [1.5-4]
hct 62 [42-51] Monos 0.8 [.2-.8]
MCV 75 [80-100] Eos 0.1 [0-0.7]
Platelets 850 [150-450] Basos 0.5 [0-0.1]
![Page 18: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/18.jpg)
![Page 19: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/19.jpg)
Bone marrow features in PV
Hypercellularity and hyperplasia of
• erythroid
• granolocytic
• megakaryocytic
cell lines
![Page 20: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/20.jpg)
![Page 21: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/21.jpg)
![Page 22: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/22.jpg)
![Page 23: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/23.jpg)
![Page 24: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/24.jpg)
PVSG Criteria for the diagnosis of Polycythemia Vera
Major criteria
1. Total red cell mass
Male >36
Female >32
2. Arterial oxygen saturation > 92
3. Splenomegaly
Minor criteria1. Thrombocytosis
(platelets > 400)
2. Leukocytosis
(WBC > 12)
3. Increased leukocyte alkaline phosphates (LAP) score
4. Serum B12 >900
![Page 25: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/25.jpg)
Criteria for diagnosis of PV
According to the Polycythemia Vera Study Group:
• All 3 major criteria OR
• The first 2 major criteria (increased red cell mass and O2 >92%) and two minor criteria.
![Page 26: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/26.jpg)
Treatment of PV
• Treatment approaches based on degree of thrombosis risk.
• Risk factors include age, platelet count (>1,500 high risk), and pregnancy.
• Low risk - phlebotomy alone or with low-dose aspirin.
• Intermediate risk - add interferon alpha• High risk - add hydoxyurea
![Page 27: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/27.jpg)
PV Therapeutic Modalities
• Phlebotomy
• Cytostatic agents
• Radioactive Phosphorus
• Hydroxyurea
• Interferon-alpha
• Anagrelide
• Stem Cell Transplant
![Page 28: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/28.jpg)
Phlebotomy
• First choice for erythrocytosis
• Target hct <45
• Remove 250 to 500 cc of blood q.o.d.
• In elderly remove 200 to 300 cc b.i.w.
![Page 29: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/29.jpg)
![Page 30: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/30.jpg)
![Page 31: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/31.jpg)
Phlebotomy
Unfortunately, none of this blood is donated.
Phlebotomized blood is discarded!
![Page 32: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/32.jpg)
Phlebotomy alone will NOT control
• thrombocytosis
• leukocytosis
• painfully enlarging spleen
• hyperuricemia or
• pruritisPatients treated with phlebotomy alone have high
incidence of fatal or disabling thrombotic events. (Wasserman, Berk, & Berlin, 1995)
![Page 33: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/33.jpg)
Cytostatic Agents for Myelosuppression
• Leukeran was commonly used.
• But leukeran increased leukemia risk
• Other drugs:– melphalan– cyclophosphamide– busulfan – but risk of life-threatening thrombyocytopenia
![Page 34: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/34.jpg)
Radioactive Phosphorus
• Has been used for more than 50 years
• Administered IV
• No radiation sickness
• Ameliorates abnormal physical findings– bright red skin color disappears in most – about 2/3 of enlarged spleens and livers become
non-palpable after treatment
(Wasserman, Berk, & Berlin, 1995)
![Page 35: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/35.jpg)
![Page 36: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/36.jpg)
Hydroxyurea
• Used in patients in whom phlebotomy is problematic
• Brand name “Droxia”
• Administered p.o.
• Warning! - drug is mutagenic
• Side effects include rash, GI complaints, oral ulcers, fever.
![Page 37: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/37.jpg)
Recombinant Interferon-alpha
• PV is an off-label indication
• t.i.w. subcutaneous injection
• can reduce frequency of phlebotomy
• spleen size reduced
• Cost $50 to 150 per injection
• Side effects - depression and suicidal ideation, flu-like symtpomes
![Page 38: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/38.jpg)
Anagrelide
• Platelet inhibitor
• FDA approved 1997 “Orphan Drug”
• Cost $600/month
• Usual dose: 0.5 to 1 mg b.i.d. p.o.
• Adverse effects - positive inotropic effect
• Use caution in heart disease, renal insufficiency, hepatic dysfunction
![Page 39: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/39.jpg)
Stem Cell Transplant
• Recent study at Fred Hutchinson Cancer Research Center, Seattle, WA
• 25 patients with advanced essential thrombocythemia (n=13) or PV (n=12) received stem cell transplants.
• 64% three year survival rate
![Page 40: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/40.jpg)
PV Complications and Treatment
• Hyperuricemia - treat with allopurinol
• Peptic ulcer disease - conventional Rx
• Acute leukemia- poor prognosis
• Thromboembolic risk - aspirin use controversial
• Hemorrhagic complications - blood and/or platelet transfusions
![Page 41: Polycythemia Vera](https://reader033.vdocument.in/reader033/viewer/2022061517/56813f65550346895daa3b3b/html5/thumbnails/41.jpg)
ReferencesHobbbrand, A.V., & Pettit, J.E., 1988. Sandoz Atlas of Clinical
Hematology. London: Gower Medical.
Lee, 1999. Wintrobe’s Clinical Hematology, 10th Ed. Philadelphia: Lippincott, Williams, & Wilkins.
Mazza, J.J., 2002. Manual of clinical hematology, 3rd Ed. Philadelphia: Lippincott, Williams, & Wilkins.
Mosby’s Drug Consult, 2002.
Tefferi, A, Solberg, L.A., & Silverstein, M.N., 2000. A clinical update in polycythemia vera and essential thrombocythemia. American Journal of Medicine, 109, (2), 141-149.
Wasserman, L.R., Berk, P.D, & Berlin, N.I., 1995. Polycythemia Vera and the myeloproliferative disorders. Philadelphia: Saunders.